Poland

BMI View: As the privatisation of Poland's state-owned drugmakers and distributors draws to an end, it seems that domestic firms have been the main winners in the three-year process.... 2011-11-07

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: Poland has a well-structured medicine pricing and reimbursement system and has a relatively transparent approval process. The government plays a significant role in the funding... 2011-10-17

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, we maintain our view that the long-term growth potential of this region is favourable,... 2011-08-25

BMI View: Late-stage revisions to Poland's pharmaceutical reimbursement act have been broadly positive for pharmaceutical companies operating in this market. However, the central premise... 2011-06-23

BMI View: The availability for acquisition of Polish drugmaker Polfa Warszawa offers an attractive opportunity to pharmaceutical companies to expand their presence in a rapidly growing,... 2011-03-22